Taken together, our findings offer the first evidence of a CK2α‐FUNDC1‐ferroptosis axis in MASLD and support targeting this pathway to enhance mitochondrial integrity, and combat ferroptosis, and MASLD progression. The gene discussed is FUNDC1; the disease is metabolic dysfunction-associated steatotic liver disease.